Department of Comparative Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Biol Reprod. 2020 Aug 4;103(2):318-322. doi: 10.1093/biolre/ioaa078.
Contributions from a diverse set of scientific disciplines will be needed to help individuals make fully informed decisions regarding contraceptive choices least likely to promote HIV susceptibility. This commentary recaps contrasting interpretations of results from the Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial, a study that compared HIV risk in women using the progestin-only injectable contraceptive depot medroxyprogesterone acetate (DMPA) vs. two other contraceptive choices. It also summarizes results from basic and translational research that establish biological plausibility for earlier clinical studies that identified enhanced HIV susceptibility in women using DMPA.
需要来自不同科学领域的贡献，以帮助个人就最不可能增加 HIV 易感性的避孕选择做出充分知情的决策。这篇评论总结了对避孕方法选择和 HIV 结局的证据（ECHO）试验结果的不同解释，该研究比较了使用单纯孕激素注射避孕药醋酸甲羟孕酮（DMPA）与另外两种避孕方法的女性的 HIV 风险。它还总结了基础和转化研究的结果，这些研究为更早的临床研究提供了生物学依据，这些研究确定了使用 DMPA 的女性 HIV 易感性增强。
